1800 244 735

Helpline (02) 9874 9777

HDBuzz takes your questions to the annual therapeutics meeting of CHDI

Over the last few years, CHDI Inc. has become the largest single driving force behind the development HD treatments. CHDI’s annual therapeutics conference in Palm Springs, California, brings together pharmaceutical companies, biotechnology companies and researchers to share their latest, hottest findings and talk about the path to a cure. HDBuzz will be reporting from the conference – and we want your questions!

CHDI

Many HD people have probably never heard of CHDI Inc. That should change, because CHDI and HD family members share the same goal. CHDI’s website explains that its aim is to “rapidly discover and develop drugs that delay or slow Huntington’s Disease”. That’s a goal that we can all get behind.

So what is CHDI, and how does it fit into the HD research picture?

CHDI is a not-for-profit ‘virtual biotechnology’ company. That means they have a number of scientists working full time on HD. But rather than work on one project at a time with their own hands, each scientist at CHDI manages a number of external projects. They work with academic labs, as well as commercial organizations that perform research on a contractual basis. In this way, CHDI is able to conduct a huge amount of basic research for an organization of its size.

Annual Therapeutics Meeting

For the last six years, CHDI has held a conference to bring together the top minds in HD research for four days of idea-sharing and discussion about how make therapies a reality.

There are lots of academic conferences, but the CHDI meeting is a unique experience. The relationships CHDI has developed with collaborators straddle the worlds of academic and clinical research, as well as the commercial side of making drugs.

It’s pretty rare to get such a broad range of expertise at a single scientific meeting, and it fosters unique collaborations between academic researchers and commercial organizations. Also, because CHDI’s mission is so clear, each year there’s a very intense focus on patients, and how to turn ideas into treatments.

This year promises significant updates from many scientists. There will be a whole morning of presentations focusing on strategies to reduce the levels of the huntingtin protein. These approaches include gene silencing with siRNA, an avenue that many in the community are excited about. Other sessions include efforts to understand the energy problems observed in HD, the use of growth factors for therapy, and other exciting areas of research.

The Research Pipeline

Developing a drug is a long process. It starts when a scientist makes an observation that helps explain how a disease happens. Turning that knowledge into a drug requires a complicated set of steps.

First, molecules have to be discovered that can alter the process. Usually that’s developed in isolated cells. Next, the drug has to be tested in animal models of the disease, beginning with simple ones like fruit flies and progressing to more complex animals like mice.

If the drugs continue to work, they need to be tested for toxicity, to ensure that they don’t have terrible side effects. Finally, if they’re safe and effective in animals, they have to be tested in people.

Organizations that develop drugs usually work on many different drugs at any given time. They talk of a ‘pipeline’ of drugs – some very early in development, and some more advanced. CHDI has its own pipeline of drugs in development, and this year’s meeting includes an exciting-sounding talk entitled ‘CHDI’s Internal Late Stage Programs’.

Questions for CHDI? Send them to us!

HDBuzz has been granted an exclusive interview with the senior management of CHDI at this year’s meeting. We’ll be sitting down with Robert Pacifici, CHDI’s Chief Scientific Officer, as well as the Vice Presidents of Biology (Ignacio Muñoz-Sanjuan) and Chemistry (Celia Dominguez). We hope this will be a unique opportunity for HD patients and families to hear about CHDI and its drug development work.

We’d like to hear from you. If you had the chance to sit down with the people directing a large portion of HD research, what would you want to know? Do you have questions about where particular branches of research stand?

Send your questions to us at CHDI2011@HDBuzz.net and we’ll pose them to CHDI management. This is your chance to ask direct questions about the state and future of HD research from the people leading it. Let your voice be heard!

HDBuzz, live from Palm Springs

Each evening of the conference, HDBuzz editors and writers will post a daily update article to HDBuzz.net, capturing all the most cutting edge research, in plain language.

Then, towards the end of the conference, we’ll post another article reporting on our interview with CHDI management. Get your questions in to CHDI2011@HDBuzz.net!

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Published date: 15 July, 2020

Dopamine is an important chemical messenger in the brain that becomes imbalanced in Huntington’s disease. Researchers recently described a creative way to restore the balance and treat symptoms in HD mice, using an antihistamine drug that acts on hybrid dopamine receptors. It’s an innovative approach to HD therapeutics, but don’t start reaching for allergy meds ... Read more HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.